[Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients]

Area of Science:

• Nephrology
• Endocrinology
• Orthopedics

Background:

• Chronic kidney disease-mineral bone disease (CKD-MBD) is a critical prognostic factor for mortality, particularly in dialysis patients.
• Bone disease in dialysis patients is complex, influenced by multiple factors beyond postmenopausal osteoporosis.
• Traditional bone mineral density assessments (e.g., DEXA) and metabolic markers are inadequate for evaluating bone fragility in this population.

Purpose of the Study:

• To highlight the limitations of current bone assessment methods in dialysis patients.
• To emphasize the increased fracture risk and potential link to malnutrition in end-stage renal disease (ESRD).
• To underscore the importance of understanding CKD-MBD's impact on mortality and cardiovascular disease prevention in clinical practice.

Main Methods:

• Review of existing literature on CKD-MBD and bone disease in dialysis patients.
• Analysis of the prevalence of bone fractures in ESRD compared to the general population.
• Discussion of current therapeutic guidelines for CKD-MBD.

Main Results:

• Bone disease in dialysis patients is heterogeneous and not solely due to postmenopausal osteoporosis.
• Bone fracture prevalence is 3-4 times higher in ESRD patients.
• Skeletal fractures in ESRD may be linked to malnutrition.

Conclusions:

• Standard bone assessments are insufficient for evaluating bone fragility in dialysis patients.
• Therapeutic guidelines for CKD-MBD primarily focus on cardiovascular disease and mortality prevention.
• Clinicians must possess a thorough understanding of CKD-MBD's multifaceted effects in daily practice.